Author: admin

Boston residents using BCCE have saved $200 per year on average on their electricity bills, saving ratepayers nearly $260 million since the program’s start in 2021

The City of Boston announced new electricity rates for the Boston Community Choice Electricity (BCCE) program, allowing Boston residents and small businesses to save money on their energy bills. These rates, which go into effect this month, are lower than current and upcoming Eversource rates, providing residents and small businesses electricity bill savings and renewable energy. Between February 2021 and December 2024, Boston residents using BCCE averaged savings of $200 per year on their electricity bills, in comparison to the Eversource Basic Service, saving Boston residents and small businesses nearly $260 million over those three years. BCCE’s new rates will remain in effect for the next two years. 

The City encourages all residents and small businesses to check their electricity bill to confirm their enrollment in Boston Community Choice Electricity. Many residents who are not enrolled in BCCE are unknowingly paying too much for electricity because they are receiving electricity from a third-party supplier. Third-party electricity suppliers often take advantage of low-income residents and people of color through offering low introductory rates, significantly raising the rates later, and by charging high termination fees. To get help checking your energy supplier or to enroll in BCCE, contact the City of Boston’s BCCE team by scheduling an appointment, emailing BCCE@boston.gov or calling 617-635-3850.

“The new electricity rates through Boston Community Choice Electricity give Boston residents an opportunity to reduce their utility bills at a time when many families are struggling with our country’s affordability crisis,” said Mayor Michelle Wu. “This program proves that here in Boston, energy savings and bold solutions to tackle climate change go hand-in-hand.”

About 65 percent of all Boston rate payers are currently enrolled in BCCE, and new utility account holders are automatically enrolled in the program. The BCCE Basic and Standard rates are both lower than the Eversource Basic Commercial and Residential rates. Below is a comparison of the cost savings per kilowatt hour, as well as the updated BCCE rates for 2026.

A comparison of current Boston Community Choice Electricity rates to Eversource’s upcoming Basic Residential rate.

Eversource’s winter rates are $0.15065/kWh for the Residential plan, and $0.14466/kWh for Commercial. Eversource has also filed a Basic Service Cost Adjustment with the Massachusetts Department of Public Utilities which, if approved, may increase the Eversource Basic Service rates by an additional $0.00565/kWh.

Despite federal cuts to eliminate renewable energy projects, Boston continues to prioritize clean energy and remains focused on reaching carbon neutrality by 2050. This month, the BCCE Program increased the enrollment cap for commercial and industrial accounts from 1.5 million kWh/yr to 2 million, allowing more Boston businesses to enroll in BCCE, save money on utility costs, and switch to renewable energy. Between 2021-2024, BCCE reduced Boston’s Carbon footprint by nearly 200,000 tons of CO2, the equivalent of taking approximately 46,000 gasoline-powered passenger vehicles off the road for a year.

“Boston Community Choice Electricity is putting money back in the wallets of Boston residents,” said Oliver Sellers-Garcia, Environment Commissioner and Director of the Green New Deal for the City of Boston. “Our program shows that clean energy is a win-win for our community, reducing pollution in our neighborhoods while saving our families and small businesses money.”

Energy Cost Saving Opportunities for Boston Residents

In October, Mayor Michelle Wu announced the launch of Boston Energy Saver, a new City service helping Boston renters, homeowners, and small businesses upgrade their buildings and lower their energy bills. Currently, there are many energy programs available to consumers, but it can be difficult to understand where to start. Residents can visit boston.gov/save or call 617-635-SAVE (7283) for a 1-on-1 consultation about available discounts and building upgrade options to save money on energy costs. Potential upgrades include rebates and low-cost financing for energy upgrades, building weatherization, heat pumps, induction stoves, and energy bill check-ups to make sure residents are not being overcharged, among others.

Avoid Scams this Winter

Scammers posing as utility representatives are on the rise. Beware of sophisticated scams that ask you for sensitive information or require immediate payment in the form of gift cards or face utility shutoff. Direct Energy (the energy supplier for BCCE), the City of Boston, and local utilities will never contact you making these requests. Residents can contact BCCE at 617-635-3850 or email bcce@boston.gov with any questions about scam attempts.

GALWAY, Ireland, Dec. 19, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its Diabetes business, which as previously announced will operate under the name MiniMed, has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed initial public offering (IPO) of newly issued common stock. The separation is expected to be completed through a series of capital markets transactions, with a preferred path of an IPO and subsequent split-off. 

MiniMed intends to apply to have its common stock listed on the Nasdaq Global Select Market under the symbol MMED. The number of shares to be offered and the price range for the offering have not yet been determined. The IPO is expected to commence after the completion of the SEC review process, subject to market and other conditions.

A registration statement on Form S-1 relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations, or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”).

Goldman Sachs & Co. LLC, BofA Securities, Citigroup and Morgan Stanley will act as the active bookrunners for the proposed offering. Barclays Capital Inc., Deutsche Bank Securities Inc., Mizuho Securities USA LLC, Wells Fargo Securities, Evercore ISI and Piper Sandler & Co. will also act as joint bookrunning managers and BTIG, LLC and William Blair & Company, L.L.C. will act as co-managers. The proposed offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the proposed IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at +1-866-471-2526, by facsimile at +1-212-902-9316 or by email at prospectus-ny@ny.email.gs.com; BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, Attention: Prospectus Department, by email at dg.prospectus_requests@bofa.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; and Citigroup, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, telephone at +1-800-831-9146.

About the Diabetes Business at Medtronic
Medtronic Diabetes is on a mission to make diabetes more predictable, so everyone can embrace life to the fullest with the most advanced diabetes technology and always-on support when and how they need it. We’ve pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to Medtronic’s ability to satisfy the necessary conditions to consummate the separation of its Diabetes business on a timely basis or at all, Medtronic’s ability to successfully separate its Diabetes business and realize the anticipated benefits from the separation (including consummating the transaction on a basis that is generally tax-free to shareholders), MiniMed’s ability to succeed as a standalone publicly traded company, competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, general economic conditions, and other risks and uncertainties described in the company’s periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. In some cases, you can identify these statements by forward-looking words or expressions, such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “looking ahead,” “may,” “plan,” “possible,” “potential,” “project,” “should,” “going to,” “will,” and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances. While a split-off is the company’s current preferred separation structure, a final decision has not been reached at this time. The separation is expected to occur through a series of capital markets transactions, which may include a spin-off, split-off, offering, or combination thereof, of the company’s remaining shareholding in MiniMed. 

Medtronic Contacts
Erika Winkels
Public Relations
+1-763-526-8478

Ingrid Goldberg
Investor Relations
ingrid.goldberg@medtronic.com

Diabetes Contacts
Janet Cho
Global Communications
+1-818-403-7028

Ryan Weispfenning
Investor Relations 
+1-763-505-4626 

SOURCE Medtronic plc